{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:29:37Z","timestamp":1784021377132,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s11060-024-04617-2","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T18:01:43Z","timestamp":1709661703000},"page":"515-522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1"],"prefix":"10.1007","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1865-9105","authenticated-orcid":false,"given":"Brianna C.","family":"Peacock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-1042","authenticated-orcid":false,"given":"Sanjna","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6155-2226","authenticated-orcid":false,"given":"Hannah L.","family":"Hanania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1686-7760","authenticated-orcid":false,"given":"Zsila","family":"Sadighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5372-784X","authenticated-orcid":false,"given":"Anisha B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"issue":"7","key":"4617_CR1","doi-asserted-by":"publisher","first-page":"e1109","DOI":"10.1634\/theoncologist.2020-0069","volume":"25","author":"LJ Klesse","year":"2020","unstructured":"Klesse LJ, Jordan JT, Radtke HB et al (2020) The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities. Oncologist 25(7):e1109\u2013e1116. https:\/\/doi.org\/10.1634\/theoncologist.2020-0069","journal-title":"Oncologist"},{"issue":"6","key":"4617_CR2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s00381-021-05127-6","volume":"37","author":"H Toledano","year":"2021","unstructured":"Toledano H, Dotan G, Friedland R et al (2021) Trametinib for orbital plexiform neurofibromas in young children with neurofibromatosis type 1. Childs Nerv Syst 37(6):1909\u20131915. https:\/\/doi.org\/10.1007\/s00381-021-05127-6","journal-title":"Childs Nerv Syst"},{"issue":"3","key":"4617_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11060-020-03640-3","volume":"149","author":"F Selt","year":"2020","unstructured":"Selt F, van Tilburg CM, Bison B et al (2020) Response to trametinib treatment in progressive pediatric low-grade glioma patients. J Neurooncol 149(3):499\u2013510. https:\/\/doi.org\/10.1007\/s11060-020-03640-3","journal-title":"J Neurooncol"},{"issue":"2","key":"4617_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/pde.14354","volume":"38","author":"VL D\u00e1vila Osorio","year":"2021","unstructured":"D\u00e1vila Osorio VL, Vicente MA, Baselga E, Salvador H, Cruz O, Prat C (2021) Adverse cutaneous effects of mitogen-activated protein kinase inhibitors in children. Pediatr Dermatol 38(2):420\u2013423. https:\/\/doi.org\/10.1111\/pde.14354","journal-title":"Pediatr Dermatol"},{"key":"4617_CR5","doi-asserted-by":"publisher","first-page":"noac146","DOI":"10.1093\/neuonc\/noac146","volume":"3","author":"MJ Fisher","year":"2022","unstructured":"Fisher MJ, Blakeley JO, Weiss BD et al (2022) Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol Published Online June 3:noac146. https:\/\/doi.org\/10.1093\/neuonc\/noac146","journal-title":"Neuro Oncol Published Online June"},{"issue":"2","key":"4617_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1200\/JGO.2015.000802","volume":"1","author":"O Abdel-Rahman","year":"2015","unstructured":"Abdel-Rahman O, ElHalawani H, Ahmed H (2015) Risk of selected cardiovascular poxicities in patients with cancer treated with MEK inhibitors: a comparative systematic review and meta-analysis. J Global Oncol 1(2):73\u201382. https:\/\/doi.org\/10.1200\/JGO.2015.000802","journal-title":"J Global Oncol"},{"issue":"11","key":"4617_CR7","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1586\/17474124.2015.1087847","volume":"9","author":"O Abdel-Rahman","year":"2015","unstructured":"Abdel-Rahman O, ElHalawani H, Ahmed H, Ellithy M (2015) Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 9(11):1433\u20131445. https:\/\/doi.org\/10.1586\/17474124.2015.1087847","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"4617_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40257-014-0088-2","volume":"15","author":"L Peuvrel","year":"2014","unstructured":"Peuvrel L, Dr\u00e9no B (2014) Dermatological toxicity associated with targeted therapies in cancer: optimal management. Am J Clin Dermatol 15(5):425\u2013444. https:\/\/doi.org\/10.1007\/s40257-014-0088-2","journal-title":"Am J Clin Dermatol"},{"issue":"24","key":"4617_CR9","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.2217\/fon.15.265","volume":"11","author":"O Abdel-Rahman","year":"2015","unstructured":"Abdel-Rahman O, ElHalawani H, Ahmed H (2015) Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. Future Oncol 11(24):3307\u20133319. https:\/\/doi.org\/10.2217\/fon.15.265","journal-title":"Future Oncol"},{"issue":"6","key":"4617_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40257-020-00539-7","volume":"21","author":"CJ Wang","year":"2020","unstructured":"Wang CJ, Brownell I (2020) Braf inhibitors for the treatment of papulopustular eruptions from MAPK pathway inhibitors. Am J Clin Dermatol 21(6):759\u2013764. https:\/\/doi.org\/10.1007\/s40257-020-00539-7","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"4617_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1468-3083.2012.04546.x","volume":"27","author":"I Manousaridis","year":"2013","unstructured":"Manousaridis I, Mavridou S, Goerdt S, Leverkus M, Utikal J (2013) Cutaneous side effects of inhibitors of the RAS\/RAF\/MEK\/ERK signaling pathway and their management: cutaneous side effects of inhibitors of the RAS\/RAF\/MEK\/ERK. J Eur Acad Dermatol Venereol 27(1):11\u201318. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04546.x","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"4617_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.det.2021.12.007","volume":"40","author":"DW Linggonegoro","year":"2022","unstructured":"Linggonegoro DW, Song H, Huang JT (2022) Supportive oncodermatology in pediatric patients. Dermatol Clin 40(2):203\u2013214. https:\/\/doi.org\/10.1016\/j.det.2021.12.007","journal-title":"Dermatol Clin"},{"issue":"1","key":"4617_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/neuonc\/noq141","volume":"13","author":"B Geoerger","year":"2011","unstructured":"Geoerger B, Hargrave D, Thomas F et al (2011) Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing\/refractory brain tumors. Neurooncology 13(1):109\u2013118. https:\/\/doi.org\/10.1093\/neuonc\/noq141","journal-title":"Neurooncology"},{"issue":"8","key":"4617_CR14","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1002\/ijc.31603","volume":"143","author":"E Van Cutsem","year":"2018","unstructured":"Van Cutsem E, Hidalgo M, Canon JL, Macarulla T, Bazin I, Poddubskaya E et al (2018) Phase I\/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. Int J Cancer 143(8):2053\u20132064. https:\/\/doi.org\/10.1002\/ijc.31603","journal-title":"Int J Cancer"},{"issue":"6","key":"4617_CR15","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1016\/j.jaad.2020.07.044","volume":"84","author":"CL Boull","year":"2021","unstructured":"Boull CL, Gardeen S, Abdali T, Li E, Potts J, Rubin N et al (2021) Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: a multicenter study. J Am Acad Dermatol 84(6):1554\u20131561. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.044","journal-title":"J Am Acad Dermatol"},{"issue":"22","key":"4617_CR16","doi-asserted-by":"publisher","first-page":"5525","DOI":"10.1158\/1078-0432.CCR-18-0494","volume":"24","author":"RN Grisham","year":"2018","unstructured":"Grisham RN, Moore KN, Gordon MS, Harb W, Cody G, Halpenny DF et al (2018) Phase ib study of Binimetinib with Paclitaxel in patients with platinum-resistant ovarian Cancer: final results, potential biomarkers, and Extreme responders. Clin Cancer Res 24(22):5525\u20135533. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0494","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4617_CR17","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/bjc.2017.271","volume":"117","author":"A Greystoke","year":"2017","unstructured":"Greystoke A, Steele N, Arkenau HT, Blackhall F, Md Haris N, Lindsay CR et al (2017) SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLCin the first-line setting. Br J Cancer 117(7):938\u2013946. https:\/\/doi.org\/10.1038\/bjc.2017.271","journal-title":"Br J Cancer"},{"issue":"1","key":"4617_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1470-2045(12)70489-8","volume":"14","author":"PA J\u00e4nne","year":"2013","unstructured":"J\u00e4nne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C et al (2013) Selumetinib plus Docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo- controlled, phase 2 study. Lancet Oncol 14(1):38\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(12)70489-8","journal-title":"Lancet Oncol"},{"issue":"1","key":"4617_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/annonc\/mdu482","volume":"26","author":"AW Tolcher","year":"2015","unstructured":"Tolcher AW, Bendell JC, Papadopoulos KP, Burris HA, Patnaik A, Jones SF et al (2015) A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Ann Oncol 26(1):58\u201364. https:\/\/doi.org\/10.1093\/annonc\/mdu482","journal-title":"Ann Oncol"},{"issue":"10","key":"4617_CR20","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/bjc.2015.126","volume":"112","author":"Z Eroglu","year":"2015","unstructured":"Eroglu Z, Tawbi HA, Hu J, Guan M, Frankel PH, Ruel NH et al (2015) A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas. Br J Cancer 112(10):1644\u20131651. https:\/\/doi.org\/10.1038\/bjc.2015.126","journal-title":"Br J Cancer"},{"issue":"8","key":"4617_CR21","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1007\/s00381-021-05138-3","volume":"37","author":"JPM P\u00e9rez","year":"2021","unstructured":"P\u00e9rez JPM, Muchart J, L\u00f3pez VSM, Capella MS, Salvador N, Jaume SP et al (2021) Targeted therapy for pediatric low-grade glioma. Childs Nerv Syst 37(8):2511\u20132520. https:\/\/doi.org\/10.1007\/s00381-021-05138-3","journal-title":"Childs Nerv Syst"},{"issue":"4","key":"4617_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/annonc\/mdw008","volume":"27","author":"CA Carter","year":"2016","unstructured":"Carter CA, Rajan A, Keen C, Szabo E, Khozin S, Thomas A et al (2016) Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol 27(4):693\u2013699. https:\/\/doi.org\/10.1093\/annonc\/mdw008","journal-title":"Ann Oncol"},{"issue":"1","key":"4617_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11523-016-0469-y","volume":"12","author":"JL Van Laethem","year":"2017","unstructured":"Van Laethem JL, Riess H, Jassem J, Haas M, Martens UM, Weekes C et al (2017) Phase I\/II study of Refametinib (BAY 86-9766) in combination with Gemcitabine in Advanced pancreatic cancer. Target Oncol 12(1):97\u2013109. https:\/\/doi.org\/10.1007\/s11523-016-0469-y","journal-title":"Target Oncol"},{"issue":"12","key":"4617_CR24","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.ejca.2014.04.024","volume":"50","author":"JR Infante","year":"2014","unstructured":"Infante JR, Somer BG, Park JO, Li CP, Scheulen ME, Kasubhai SM et al (2014) A randomised, double- blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer 50(12):2072\u20132081. https:\/\/doi.org\/10.1016\/j.ejca.2014.04.024","journal-title":"Eur J Cancer"},{"key":"4617_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.lungcan.2019.04.027","volume":"133","author":"B Melosky","year":"2019","unstructured":"Melosky B, Bradbury P, Tu D, Florescu M, Reiman A, Nicholas G et al (2019) Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: a randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219. Lung Cancer 133:48\u201355. https:\/\/doi.org\/10.1016\/j.lungcan.2019.04.027","journal-title":"Lung Cancer"},{"issue":"suppl1","key":"4617_CR26","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","volume":"29","author":"WH Hsu","year":"2018","unstructured":"Hsu WH, Yang JC, Mok TS, Loong HH (2018) Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol 29(suppl1):i3\u2013i9. https:\/\/doi.org\/10.1093\/annonc\/mdx702","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"4617_CR27","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.3816\/clc.2006.s.008","volume":"8","author":"R Perez-Soler","year":"2006","unstructured":"Perez-Soler R (2006) Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 8(Suppl 1):S7\u2013S14. https:\/\/doi.org\/10.3816\/clc.2006.s.008","journal-title":"Clin Lung Cancer"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04617-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T13:06:10Z","timestamp":1715778370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04617-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["4617"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04617-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"24 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was granted by the Institutional Review Board (IRB) of MD Anderson Cancer Center (Dec 2015, PA15-0959).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This research was covered by a waiver of consent by the IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}